

Complement Interaction with Trypanosomatid Promastigotes in Normal Human Serum

Mercedes Domínguez,¹ Inmaculada Moreno,¹
Margarita López-Trascasa,² and Alfredo Toraño¹

¹Servicio de Inmunología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, E-28220 Madrid, Spain

²Unidad de Inmunología, Hospital La Paz, E-28046 Madrid, Spain

Abstract

In normal human serum (NHS), axenic promastigotes of *Crithidia*, *Phytomonas*, and *Leishmania* trigger complement activation, and from 1.2 to 1.8×10^5 C3 molecules are deposited per promastigote within 2.5 min. In *Leishmania*, promastigote C3 binding capacity remains constant during in vitro metacyclogenesis. C3 deposition on promastigotes activated through the classical complement pathway reaches a 50% maximum after ~ 50 s, and represents $>85\%$ of total C3 bound. In C1q- and C2-deficient human sera, promastigotes cannot activate the classical pathway (CP) unless purified C1q or C2 factors, respectively, are supplemented, demonstrating a requirement for CP factor in promastigote C3 opsonization. NHS depleted of natural anti-*Leishmania* antibodies cannot trigger promastigote CP activation, but IgM addition restores C3 binding. Furthermore, *Leishmania* binds natural antibodies in ethylenediaminetetracetic acid (EDTA)-treated NHS; after EDTA removal, promastigote-bound IgM triggers C3 deposition in natural antibody-depleted NHS. Serum collectins and pentraxins thus do not participate significantly in NHS promastigote C3 opsonization. Real-time kinetic analysis of promastigote CP-mediated lysis indicates that between 85–95% of parasites are killed within 2.5 min of serum contact. These data indicate that successful *Leishmania* infection in man must immediately follow promastigote transmission, and that *Leishmania* evasion strategies are shaped by the selective pressure exerted by complement.

Key words: Trypanosomatids • *Leishmania* • complement opsonization • promastigote lysis • human serum

Introduction

Leishmania protozoa, the etiologic agents of the leishmanioses, are transmitted to vertebrate hosts by the bite of sandflies of the genera *Phlebotomus* (Old World) and *Lutzomyia* (New World). Phlebotomine sandflies infect mammals by inoculating promastigotes into hemorrhagic spots created in the skin while probing for a blood meal. In contact with normal human blood, *Leishmania* promastigotes trigger complement activation and C3 opsonization (1). Analysis of early promastigote–host cell interactions using an ex vivo model of *Leishmania* human blood infection indicates that after C3 opsonization, promastigotes undergo an immune adherence (IA)* reaction and bind to CR1 erythrocyte re-

ceptors (2). Further studies showed that *Leishmania*–platelet binding, a primitive form of *Leishmania*–erythrocyte IA, occurs after promastigote contact with blood of nonprimate mammals, confirming that promastigote IA is the first *Leishmania* interaction with mammalian cells after infection (3). The immune adherent promastigotes are thereafter endocytosed by blood phagocytes, and undergo physiological and phenotypic transformations inside the phagolysosomes, which culminate in the vertebrate-dwelling amastigote forms (4).

During *Leishmania* host invasion, complement-mediated promastigote killing can compromise parasite survival. Identification of promastigote opsonization by host serum is thus essential to understanding *Leishmania* infection strategy. Pioneering studies on promastigote opsonization in normal

Address correspondence to Alfredo Toraño, Servicio de Inmunología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, E-28220 Madrid, Spain. Phone: 34-91-509-7973; Fax: 34-91-509-7966; E-mail: atorano@isci.es

*Abbreviations used in this paper: Ads-NHS, adsorbed NHS; AP, alternative complement pathway; C1qDS, serum deficient in C1q complement component; C2DS, serum deficient in C2 complement factor; CP, classical

complement pathway; CRP, C-reactive protein; IA, immune adherence; IRF, immune reactive fraction; MBL, mannan-binding lectin; NAb, natural antibody; PI, propidium iodide.

human serum (NHS) indicated that IgM anti-*Leishmania* antibodies were responsible for promastigote agglutination, classical complement pathway (CP) activation, and parasite killing (5, 6). Despite these data, understanding of the promastigote opsonization mechanism has to date been dominated by the concept that *Leishmania* spp. promastigotes activate complement in NHS through the alternative pathway (AP), thus lacking antibody involvement (7–9). Exceptions to this rule have been reported for *Leishmania donovani* promastigotes (8) and axenic metacyclic peanut agglutinin-negative forms of *Leishmania major* (10), but the view prevails that leishmanias activate complement via the AP (11, 12).

In addition to promastigote-C3 opsonization by the classical and alternative routes, it is also reported that two specific carbohydrate-binding proteins in serum, mannan-binding lectin (MBL) and the acute phase protein C-reactive protein (CRP), bind *Leishmania* parasites (13–15); they thus could initiate promastigote opsonization through a novel antibody- and C1-independent mechanism, the lectin-mediated pathway.

To clarify this issue, we performed a comprehensive quantitative and kinetic analysis of promastigote opsonization in NHS in near-physiological conditions using promastigote cell binding assays, high opsonizing serum concentrations (25–100%), and short incubation times (≤ 3 min). The results indicate that binding of natural IgM anti-*Leishmania* antibodies (NAb) to conserved trypanosomatid epitopes triggers C3 parasite opsonization, and that serum collectins (MBL) and pentraxins (CRP) do not participate significantly in complement activation. In NHS, promastigotes activate complement CP and AP simultaneously, but >85% of promastigote-bound C3 is generated through the CP, indicating that physiological C3 opsonization of *Leishmania* is activated through the CP in a natural infection. In the early infection period, promastigote lysis by complement parallels the course of C3 deposition (2). As real-time data on this mechanism were lacking, we measured real-time kinetics of promastigote killing in 50% NHS, and show that from 85–95% of stationary culture promastigotes become permeable to propidium iodide in <3 min after serum contact. Human infection by *Leishmania* is thus an extremely rapid process, and promastigotes must display evasion strategies immediately after inoculation to avoid lysis by complement.

Materials and Methods

Parasites and Cultures. Trypanosomatids studied were *Leishmania donovani* Khartoum 1246 (MHOM/SD/43/124), *Leishmania amazonensis* Maria (MHOM/Br/79/Maria), *Leishmania infantum* PB75 (MHOM/Fr/LEM75), *L. major* NIH 173 (MHOM/IR/-/173), *Crithidia fasciculata*, and *Phytomonas characias*. *Leishmania* and *Crithidia* promastigotes were cultured in RPMI 1640, and *Phytomonas* in Grace's medium (both from GIBCO BRL/Life Technologies), supplemented with 10% heat-inactivated FCS (Imperial Labs), 2 mM L-glutamine, 100 IU/ml penicillin, and 100 μ g/ml streptomycin (complete medium). Cultures were in-

cubated at 26°C. Stationary phase parasites were harvested and handled as described previously (2).

Antibodies and Human Sera. Blood from healthy donors was allowed to clot in siliconized glass tubes (20°C, 30 min), and serum aliquots stored in liquid nitrogen. Clinical and genetic data of sera from patients with hereditary deficiencies in complement factors C1q (C1qDS) and C2 (C2DS) have been reported elsewhere (16, 17). Anti-human C3 α chain mAb SIM27-49, IgG2b, developed in our laboratory, was purified from mouse ascites fluid by HiTrap-protein A treatment. NHS was adsorbed (Ads-NHS) for 30 min on ice with *L. donovani* or *L. amazonensis* promastigotes at a ratio of 1 ml of 50% PBS-diluted NHS:10⁹ pelleted promastigotes. Ads-NHS was centrifuged (11,000 g, 3 min), and the supernatant reabsorbed in two additional cycles; finally, serum was filtered through a 0.22- μ m pore membrane to remove aggregates and used in functional assays. IgM was isolated from NHS by affinity chromatography on a protamine-Sepharose CL4B column by end-over-end mixing of 20 ml 50% H₂O-diluted NHS with 10 ml packed protamine-Sepharose beads (4 h, 20°C). After incubation, the column was washed and eluted as described (18). The IgM-enriched fraction was dialyzed against PBS, filtered to remove aggregates, stored at 4°C, and used within 24 h. NHS IgG was isolated on a HiTrap Protein G column (Amersham Pharmacia Biotech). Protein content was determined by BCA assay (19). SIM27-49 (25 μ g) was labeled with 5 μ l of Na ¹²⁵Iodine (carrier-free, 105.36 mCi/ml; Dupont/NEN Life Science Products) in iodogen (Pierce Chemical Co.)-coated tubes as described (2). The [¹²⁵I]SIM27-49 immune reactive fraction (IRF) was measured by titrating a fixed, limiting amount of radiolabeled antibody against increasing concentrations of NHS-opsonized *Leishmania* promastigotes, until promastigote-bound C3 epitopes greatly exceeded [¹²⁵I]SIM27-49 paratopes. The antibody IRF was calculated by direct linear plot (20).

Kinetics of Complement Activation by *Leishmania*, *Crithidia*, and *Phytomonas* Promastigotes in NHS and Mg-EGTA-treated NHS. 50 μ l of a 2×10^8 /ml promastigote suspension were mixed with 50 μ l of 50% NHS or 50% NHS-adjusted to 10 mM EGTA, 7 mM MgCl₂ (Mg-EGTA-NHS), and incubated for varying time periods. The reaction was terminated by adding cold PBS containing 2.5% FCS and 0.05% NaN₃ (PFS) and the parasites washed twice by centrifugation (11,000 g, 1 min). The cell pellet was resuspended in 200 μ l of PFS containing 2×10^5 cpm of [¹²⁵I]SIM27-49 (specific activity 10⁷ cpm/ μ g) and incubated 1 h on ice. Promastigotes were then washed twice by centrifugation as above, and bound [¹²⁵I]SIM27-49 cpm determined. A t_{50} index (time required for each species to reach 50% maximum C3 binding) was calculated from a plot of percent-normalized promastigote-C3 binding against incubation time.

Complement Activation by *Leishmania* in C1q- and C2-deficient Sera. Duplicate 50 μ l samples of a 2×10^8 /ml *L. donovani* promastigote suspension were incubated at 37°C with 50 μ l of 50% diluted NHS, 50% diluted Mg-EGTA-treated NHS, C1qDS, or C2DS, for 0, 0.5, 3, 5, 7, and 10 min. Conditions for *L. amazonensis* assay were identical, but to compensate for activity loss during long-term storage, C2DS was used at 60% concentration. Purified C1q (125 μ g/ml) and C2 (47,500 CH50 units) were supplemented. After incubation, assay conditions were as described above for complement activation kinetics. Finally, bound [¹²⁵I]SIM27-49 cpm were determined.

Complement Activation by *Leishmania* in Ig-supplemented Ads-NHS. IgM and IgG preparations devoid of complement activity were purified as described above. All IgM and IgG preparations used showed promastigote binding $\geq 100\%$ of that observed for

25% NHS. *L. donovani* and *L. amazonensis* promastigote triggering of complement activation was analyzed in a two-step C3 binding assay. Pelleted *L. donovani* promastigotes (10^7) were resuspended in 100 μ l of 25% NHS adjusted to 10 mM EDTA (NHS-EDTA), purified IgM adjusted to 10 mM EDTA (IgM-EDTA), or purified IgG adjusted to 10 mM EDTA (IgG-EDTA), and incubated (37°C, 30 s). Promastigotes were then washed twice by centrifugation (11,000 g, 1 min). Promastigote pellets preincubated in NHS-EDTA were resuspended in 100 μ l of 25% NHS (positive control) or 25% *L. donovani* Ads-NHS; promastigotes preincubated in IgM-EDTA or IgG-EDTA were resuspended in 100 μ l of 25% of *L. donovani* Ads-NHS. Tubes were incubated (2 min, 37°C), followed by two centrifugation washes (11,000 g, 1 min). Promastigotes were resuspended in 0.2 ml PFS containing 2×10^5 [125 I]SIM27–49 cpm and incubated (1 h, on ice). After two further washes, bound cpm were determined. Control samples for classical and alternative complement pathway activation were not preincubated. To study CP activation, 10^7 pelleted *L. donovani* promastigotes were resuspended in 100 μ l of 25% NHS, 25% Mg-EGTA-NHS (NHS-EGTA), 25% purified IgM, 25% purified IgG, or 25% *L. donovani*-Ads-NHS, and incubated (2 min, 37°C). For AP activation, promastigotes were resuspended in 100 μ l of 25% NHS, 25% NHS-EGTA, or 25% *L. donovani*-Ads-NHS, and incubated (15 min, 37°C). Samples were washed twice by centrifugation, promastigotes resuspended in 0.2 ml of PFS containing 2×10^5 cpm [125 I]SIM27–49, incubated 1 h on ice, and processed as above. NHS complement activation by *L. amazonensis* was measured similarly using *L. amazonensis*-Ads-NHS.

Quantitation of CP-activated Promastigote-C3 Binding during In Vitro Metacyclogenesis. Cultures were seeded with 10^5 *L. amazonensis* promastigotes/ml and cultured (27°C, 17 d). Promastigotes were sampled at days 3, 4, 5, 6, 7, 10, 11, 14, and 17, washed twice by centrifugation in PBS, and opsonized (10^8 promastigotes/ml in 25% PBS-diluted NHS) at 37°C for 2.5 min. Promastigotes were washed, added to duplicate tubes at concentrations of 0.625, 1.25, 2.5, 5, and 10×10^6 , adjusted to $10^7/0.1$ ml with nonopsonized promastigotes, and incubated (2 h, 0°C) with a limiting amount of [125 I]SIM27–49. After incubation, promastigotes were washed twice by centrifugation and bound [125 I]SIM27–49 cpm determined. Background cpm ([125 I]SIM27–49 cpm bound to nonopsonized promastigotes) were subtracted. A single lot of [125 I]SIM27–49 (specific activity, 6×10^6 cpm/ μ g) was used for all experiments. K_d values were calculated by direct linear plot from data of three independent cultures.

To measure CP-activated C3 binding to stationary promastigotes of *Leishmania* and *Crithidia*, parasites (10^8 cells/ml) were incubated in 25% PBS-diluted NHS (37°C, 3 min). The reaction terminated by dilution with PFS (4°C), and C3-opsonized promastigotes washed twice by centrifugation (1,500 g, 15 min). Two duplicate series of tubes containing 10^5 and 2×10^5 C3-promastigotes were adjusted to 5×10^6 promastigotes/tube with nonopsonized promastigotes. A third series of control tubes contained 5×10^6 nonopsonized promastigotes. *Leishmanias* were pelleted and resuspended in 0.2 ml PFS containing increasing concentrations of [125 I]SIM27–49, until a paratope/ligand ratio of ~ 10 was obtained. Samples were incubated on ice to equilibrium (≥ 3 h). After reaction, parasites were washed twice by centrifugation (11,000 g, 1 min) in PFS and C3-bound [125 I]SIM27–49 determined. Functional [125 I]SIM27–49 was calculated as input cpm $\times$ IRF. SIM27–49 K_d and the number of C3 molecules/promastigote were calculated by direct linear plot and Scatchard analysis (21, 22).

Real-time Kinetics of Leishmania Promastigote Lysis in NHS. Promastigote cultures of *L. major*, *L. amazonensis*, *L. donovani*, and *L. infantum* were seeded in triplicate at 10^6 cells/ml, and cell growth registered daily. Parasites were sampled at mid-log and early stationary growth phase, i.e., 2 d after the end of log-phase growth, and real-time promastigote lysis in 50% pooled NHS was analyzed by measuring propidium iodide (PI) uptake by killed promastigotes in a FACSCalibur™ flow cytometer (Becton Dickinson). The reaction was initiated by addition of 100 μ l of undiluted 0.22 μ m porefiltered NHS into a tube containing 10^5 promastigotes, 2 μ l PI (0.5 mg/ml; Sigma-Aldrich) and PBS (200 μ l final reaction volume), and incubated in a 37°C water-bath during the data acquisition period. Promastigotes were identified and gated at a forward-angle light scatter versus side-angle light scatter. PI emission was collected in the FL2 detector through a 585/42 nm band pass filter. Detector amplification was set to include untreated promastigotes (negative control) between 10^0 – 10^1 intensity. Promastigotes were acquired at a ratio of 250 events over a period of 204.8 s, with a data acquisition interval of 200 ms, and analyzed with CELLQuest™ software (Becton Dickinson). Promastigote PI uptake kinetics was analyzed in a FL2 versus time dot-plot divided into thirteen 15.98 s regions. The percentage of promastigotes incorporating PI over incubation time was quantitated for each region as number of events emitting PI fluorescence $>10^1$ /total event number (PI emitting plus nonemitting promastigotes). Controls included (a) maximum cell lysis in promastigotes treated (30 min) with acetone:methanol (1:1), (b) pooled NHS, and (c) nonspecific promastigote lysis in 10 mM EDTA-chelated 50% NHS.

Results

Kinetics of NHS Complement Activation by Trypanosomatid Promastigotes. Complement activation by trypanosomatids was analyzed by measuring NHS C3 binding kinetics to four *Leishmania* promastigote species, *L. donovani*, *L. amazonensis*, *L. infantum*, and *L. major*, and to promastigotes of two unrelated trypanosomatid genera, *C. fasciculata* and *P. characias*. In 25% PBS-diluted NHS, all trypanosomatids studied activate the classical and alternative complement pathways simultaneously. Promastigote-C3 binding via the CP is very rapid, reaching maximum within 2 to 3 min; longer incubations of up to 15 min do not increase CP C3 deposition (Fig. 1). For *Leishmania* promastigotes, the average time required to deposit 50% of total C3 bound through the CP (CPt_{50}) is ~ 50 s (49.5 ± 7 s), and 53 s for all trypanosomatids analyzed. After CP blockade with Mg-EGTA, promastigote-C3 binding kinetics follows a slower course characteristic of the AP activation mechanism. Trypanosomatid promastigotes differ in their AP activation kinetics. Plotting the percent-normalized promastigote-C3 binding against incubation time rendered a sigmoid curve for each trypanosomatid species, from which an APt_{50} index was obtained. Promastigotes can be classified by the APt_{50} index as rapid (*C. fasciculata* and *L. amazonensis*; APt_{50} 3–3.5 min), intermediate (*L. major*, *P. characias*, and *L. infantum*; APt_{50} 4.9–6.5 min), and slow (*L. donovani*; APt_{50} 8.5 min) AP activators.

At CPt_{50} , the amount of C3 deposited by the AP is at most 13.7% of total C3 binding. The CP-activated C3




Figure 1. Kinetics of C3 deposition on trypanosomatid promastigotes in NHS. Promastigotes (10^7) were incubated at 37°C in 25% NHS or 10 mM EGTA/7 mM $MgCl_2$ -treated NHS for 0, 0.5, 1, 2, 3, 4, 5, 7, 10, and 15 min. Parasites were then washed twice by centrifugation (11,000 g, 1 min) in cold PFS, and promastigote-bound C3 measured with anti-human C3 α mAb [^{125}I]SIM27-49. C3 binding (mean of duplicate values) is expressed as a percentage of the point of maximum antibody. (●) CP-activated, (○) AP-activated C3 deposition. (A) *P. characias* (3); (B) *C. fasciculata* (4); (C) *L. major* (3); (D) *L. amazonensis* (4); (E) *L. donovani* (4); (F) *L. infantum* (3). In parenthesis, the number of experiments performed for each species.

deposition rate on the promastigote surface is thus seven times faster than that activated by the AP. This indicates that promastigote C3 deposition by the CP is the functionally relevant mechanism during parasite opsonization in NHS.

Complement Activation Mechanism by *Leishmania* Promastigotes in NHS. Complement activation by the CP is Ca^{2+} and Mg^{2+} ion-dependent, whereas AP activation requires only Mg^{2+} . Differential Ca^{2+} chelation in Mg-EGTA-treated NHS thus permits identification of the activating pathway (23). To confirm that rapid and slow promastigote-C3 deposition kinetics in NHS are triggered by the CP and the AP, respectively, the C3 binding rate to *L. donovani* and *L. amazonensis* promastigotes in NHS or Mg-EGTA-treated NHS was compared with that in sera of individuals congenitally deficient in C1q or C2 early CP factors. *L. donovani* is a very slow AP activator, allowing clear separation between the CP and AP C3 binding courses (Fig. 1 E). In NHS, C3 deposition on *L. donovani* promastigotes reaches a plateau after ~3 min (Fig. 2 A), whereas the C3 binding rate is slower in C1qDS and C2DS, similar to the course followed in Mg-EGTA-treated NHS. After 3 min, the percentage of promastigote-C3 binding in C1qDS and C2DS is only 15.6 and 10.5%, respectively, of that observed in NHS. In contrast, promastigotes incubated in

C1qDS and C2DS supplemented with purified C1q and C2 factors, respectively, recover CP C3 binding kinetics and deposit 70.5% (in C1q-supplemented C1qDS) and 72.4% (C2-supplemented C2DS) of total C3 bound in NHS. *L. amazonensis* is a rapid AP-activating species, and the course of CP and AP C3 binding are closer to each other in time than in *L. donovani* (Fig. 1 D). Analysis of *L. amazonensis* promastigote-C3 deposition kinetics in C2DS, and after C2DS supplementation with C2 factor, shows results similar to those in *L. donovani* (Fig. 2 B). These data indicate that irrespective of the species analyzed, *Leishmania* promastigotes require early CP factor activity for rapid C3 binding kinetics in NHS.

Classical Complement Pathway Triggering by Natural Anti-*Leishmania* Antibodies. IgM and IgG devoid of complement activity were isolated from NHS by affinity chromatography on protamine-Sepharose, and HiTrap-protein G, respectively. NHS depleted of CP-triggering activity was prepared by adsorption with *L. donovani* or *L. amazonensis* promastigotes (Ads-NHS), as described (Materials and Methods). Promastigote activation of the CP was analyzed using a two-stage incubation assay that measures CP C3 deposition within 2 min. IgM, IgG, and Ads-NHS preparations lack the ability to trigger CP C3 deposition on promastigotes (Table I); after longer incubation (10 min), Ads-




Figure 2. Complement activation by *Leishmania* in C1q- and C2-deficient sera. Promastigotes were incubated in 50% PBS-diluted NHS (●), EGTA-NHS (○), C1qDS (□), C2DS (Δ), C1qDS supplemented with purified C1q (■), or C2DS supplemented with purified C2 (▲), and incubated at 37°C for 0, 0.5, 3, 5, 7, and 10 min. Promastigote-bound C3 was then measured with [¹²⁵I]SIM27-49. Results are expressed as a percentage of maximum [¹²⁵I]SIM27-49 binding. Each point represents the mean of duplicate samples. C1q- and C2 factor-mediated C3 binding was <5% of total C3 bound. (A) *L. donovani*; (B) *L. amazonensis*.

NHS shows AP C3 deposition capacity (89.5% for *L. amazonensis* and 66.3% for *L. donovani*) similar to that seen in NHS-EGTA (86.5% for *L. amazonensis* and 47% for *L. donovani*; not shown). Promastigotes preincubated with NHS-EDTA or IgM-EDTA, conditions that prevent promastigote MBL and CRP binding, and subsequently incubated with Ads-NHS, trigger CP C3 deposition. In contrast, promastigotes preincubated in IgG-EDTA contribute only ~18% of total C3 bound (Table I). All together, these data indicate that in NHS, natural IgM anti-*Leishmania* antibodies are the main triggering factor for CP activation by promastigotes, and that serum MBL and CRP do not contribute significantly to this process.

Quantitative Analysis of CP Promastigote-C3 Opsonization during In Vitro Metacyclogenesis. It is believed that axenic *Leishmania* cultures give rise to two developmental promastigote forms, log phase complement-sensitive and stationary phase complement-resistant (24–28). The question arises whether these differences in *Leishmania* susceptibility to complement can be ascribed to variation in the CP activating capacity of promastigote developmental stages. We thus measured CP C3 deposition on *L. amazonensis* promastigotes taken from different growth phases of in vitro metacyclogenesis. Promastigotes were sampled daily from triplicate cultures, and each sample individually opsonized in 25% NHS. Promastigote-bound C3 was titrated against [¹²⁵I]SIM 27-49, and K_d values of the C3-opsonized promastigote populations calculated. K_d values (the number of C3-opsonized promastigotes that bind 50% of [¹²⁵I]SIM 27-49 cpm) are very similar, $1.0 \pm 0.07 \times 10^6$ promastigotes/ml (mean $\pm$ SEM), irrespective of the culture growth phase. Differential susceptibility of axenic promastigote populations to complement thus cannot be ascribed to variations in their capacity to fix C3. The number of CP-activated C3 molecules bound to stationary phase *L. amazonensis*, *L. donovani*, and *C. fasciculata* promastigotes was calculated from Langmuir saturation isotherm data. On a per cell basis, *L. amazonensis* promas-

tigotes bound 1.2×10^5 , *L. donovani* 1.8×10^5 , and *C. fasciculata* 1.3×10^5 C3 molecules.

Real-time Kinetics of Leishmania Promastigote Lysis in NHS. Promastigotes of four *Leishmania* species were obtained from axenic cultures in log phase and the early stationary phase, and kinetic data on complement-mediated lysis determined by measuring PI-stained cells. Dot plots show real-time kinetics of log phase (Fig. 3 A, a–d) and early stationary phase (Fig. 3 A, e–h) promastigote killing in 50% NHS, as well as controls (Fig. 3 A, i–k). Log phase

Table I. Classical Complement Pathway Triggering of Promastigote-C3 Opsonization by Natural Anti-*Leishmania* Antibodies

Incubation		Promastigote bound C3 (%)	
		<i>L. amazonensis</i> (n)	<i>L. donovani</i> (n)
30 s	120 s		
PBS	NHS	100	100
PBS	NHS-EGTA	8.3 $\pm$ 1.7 (4)	3.2 $\pm$ 0.4 (4)
PBS	IgM	2.8 $\pm$ 1.2 (6)	3.0 $\pm$ 1.4 (6)
PBS	IgG	0.8 $\pm$ 0.6 (3)	0.6 $\pm$ 0.6 (4)
PBS	Ads-NHS	15.1 $\pm$ 2.0 (15)	11.4 $\pm$ 1.1 (24)
NHS-EDTA	NHS	100	100
NHS-EDTA	Ads-NHS	88.8 $\pm$ 4.8 (15)	71.7 $\pm$ 5.3 (26)
IgM-EDTA	Ads-NHS	88.6 $\pm$ 2.7 (13)	93.8 $\pm$ 3.6 (13)
IgG-EDTA	Ads-NHS	17.8 $\pm$ 1.4 (13)	17.4 $\pm$ 2.9 (13)

Promastigote triggering of complement activation was analyzed in a two-step binding assay. Promastigotes were preincubated (37°C, 30 s) in 100 μ l of PBS, NHS-EDTA, IgM-EDTA, or IgG-EDTA as indicated, washed twice by centrifugation, and incubated (37°C, 120 s) in the conditions indicated. Samples then were processed as described (Materials and Methods). Results are expressed as the percentage of maximum promastigote-bound C3 in NHS (100%) = SEM; (n), number of experiments performed.




Figure 3. Real-time kinetics of *Leishmania* promastigote lysis in NHS. Promastigotes were taken from log phase and early stationary phase growth cultures, and the course of parasite lysis measured in 50% NHS as described (Materials and Methods). (A) FL2 against time dot plots of log phase (a–d), and stationary phase (e–h) promastigote PI uptake in 50% NHS, as well as controls (i–k). *L. major* (a and e); *L. amazonensis* (b and f); *L. donovani* (c and g); *L. infantum* (d and h); maximum PI uptake control (i); background PI uptake control in EDTA-NHS (j); and nonspecific NHS fluorescence (k). (B) Promastigote PI uptake kinetics derived from dot plot data. Top panel: log phase promastigotes. Lower panel: early stationary phase promastigotes. *L. major* (▲); *L. amazonensis* (●); *L. donovani* (■); *L. infantum* (*).

leishmania begin to incorporate PI within 30 s of serum contact, and all cells are PI-labeled by 60 s (Fig. 3 B, top panel). Log phase promastigotes are thus highly susceptible to human complement. In contrast, PI uptake kinetics by early stationary phase promastigotes is slower; it begins within 30–60 s of serum contact, and is complete by ~2.5 min (Fig. 3 B, bottom panel). Stationary phase promastigotes show greater interspecies variability in PI uptake kinetics and percent killing (Fig. 3 B, bottom panel) than log phase promastigotes. In stationary phase *L. major* and *L. amazonensis* promastigotes, 15 and 10% of the population, respectively, show a degree of complement resistance (Fig. 3 A, e–f). The precise size of this population is difficult to calculate as, in the presence of NHS, promastigote cell volume and refractile properties are altered, blurring the distinction between promastigotes, cell debris, and NHS background signal. Stationary phase *L. donovani* and *L. infantum* promastigotes appear to be more complement susceptible (Fig. 3 A, g and h), and no motile promastigotes were observed under the microscope. Lysis of log and early stationary phase promastigotes is gradual in all four species

(Fig. 3 A, a–g); the lytic mechanism differs for *L. infantum* stationary phase promastigotes in that the entire promastigote population undergoes sudden, simultaneous death, with no intermediate stages (Fig. 3 A, h). These results indicate that in NHS, *Leishmania* promastigote lysis is an extremely rapid reaction.

Discussion

To infect their hosts, *Leishmania* promastigotes must circumvent the cytolytic effects of complement. Identification of the reaction mechanisms that govern promastigote opsonization could thus aid in comprehending *Leishmania* evasion strategies of host innate immunity. The mechanism of promastigote opsonization in NHS is the subject of controversy; some data indicate that promastigotes activate complement via the CP (2, 5, 6), but the dominant view is that *Leishmania* activation of complement is antibody independent, i.e., lectin- or AP-mediated (7–15). To elucidate this mechanism, we studied four aspects of complement-parasite interaction at near-physiological conditions, (a) the

kinetics of promastigote-C3 binding in NHS and in EGTA-NHS, (b) the requirement for early CP factors for C3 deposition, (c) the ability of anti-*Leishmania* NAb to trigger C3 deposition in Ads-NHS, and (d) complement leishmanicidal activity by measuring the real-time kinetics of promastigote killing.

In 25% NHS, promastigotes of all trypanosomatid species studied activate classical and alternative complement pathways simultaneously (Fig. 1). Promastigote-C3 deposition is extremely rapid; the reaction is complete after 2 to 3 min, at which time 86–93% of fixed C3 has been activated through the CP. The contribution of the AP to promastigote opsonization is much smaller, ranging from 7.1–13.7%. Promastigote C3 binding is traditionally measured after 15 min incubation (9, 10) or longer (30–60 min) (7, 8, 11, 12, 28). CP C3 deposition can be detected only in a narrow time window that lasts but a few minutes (Fig. 1); after this time, classical and alternative pathway kinetics merge, and only AP-dependent activity is observed. This may explain why promastigote CP C3 deposition has passed unnoticed.

AP-mediated C3 deposition has a slower time course than the CP (Fig. 1). In AP triggering, no specific recognition mechanism is involved, and both the kinetics and the amount of C3 bound are directly related to the structure of the promastigote surface. The AP pathway permits differentiation of trypanosomatids by their C3 binding kinetics and APT₅₀ values, disclosing the large intraspecies variability that exists within the subgenus *Leishmania*. *Crithidia* and *Leishmania* are genetically more distant than amphibians and mammals (29), yet larger AP kinetic differences are found among *Leishmania* species than among parasites of *Leishmania*, *Crithidia* and *Phytomonas*.

To identify the mechanism that triggers *Leishmania* opsonization in NHS, we used sera congenitally deficient in C1q or C2 complement factors. Promastigote CP C3 binding kinetics in C1q- or C2-deficient sera is restored by addition of purified C1q or C2, respectively (Fig. 2); this result supports the involvement of early CP factors in promastigote C3 opsonization. Parasite killing in C4- or C2-deficient sera (8, 12), or in normal serum depleted of natural anti-*Leishmania* antibodies (9, 11), has been taken as proof that this reaction is AP mediated. In these studies, earliest parasite lysis was measured after 15-min incubation, when AP-mediated promastigote killing is fully active. These experiments consequently provide no information on the role of the CP in the lytic mechanism, for which promastigote killing must be recorded in the early opsonization period (Fig. 1).

Candidate molecules in NHS to initiate parasite activation of the CP include anti-*Leishmania* NAb (2, 5, 6), MBL (13), and CRP (14, 15). Complement triggering was analyzed in a two-stage incubation assay that measures the ability of promastigote-bound IgM or IgG to initiate CP activity in Ads-NHS; this preparation lacks the ability to trigger CP C3 deposition. Promastigotes preincubated in NHS-EDTA or IgM-EDTA bind natural IgM anti-*Leishmania* antibodies; after a second incubation in Ads-NHS, they respectively deposit 88.8 and 88.6% of total C3 depos-

ited in NHS (Table I). In contrast, promastigotes preincubated with IgG-EDTA fix only 17.8% of total C3 bound (Table I). Triggering of CP C3 deposition by calcium-chelated NHS and protamine-isolated IgM fractions (Table I) indicates that MBL and CRP do not participate in the reaction, as their activity is calcium-dependent (14, 30). A basic requirement for the physiological *Leishmania* opsonization mechanism in NHS is that C3 deposition must be complete within 2–3 min of incubation at 37°C. MBL and CRP are reported to bind to the *Leishmania* surface (13–15), although these assays were done in far from physiological conditions (1 h in the cold). Average human plasma concentrations of MBL and CRP are 1,000–($\sim 10^{-10}$ M [31]) and 200-fold ($\sim 0.5 \times 10^{-9}$ M [14]) lower, respectively, than that of natural IgM anti-*Leishmania* antibodies ($\sim 1.6 \times 10^{-7}$ M [2]). It thus appears unlikely that they mediate the promastigote opsonization kinetics shown in Fig. 1. In chronic infections, MBL concentrations can increase 2- to 3-fold (32) and those of CRP up to 300-fold (33); MBL may thus act as an opsonin (34) and modulate disease progression (35).

Given sufficient time and suitable temperature conditions in vitro, *Leishmania* promastigotes can probably activate human complement via classical, alternative, and lectin pathways. Under quasi-physiological conditions, however, *Leishmania* opsonization is extremely rapid, and it is unlikely that MBL or CRP can account for this mechanism. We thus maintain that in NHS, natural IgM anti-*Leishmania* antibodies are the main trigger of CP activation and promastigote opsonization.

It has been proposed that parasite infective success relies on their capacity to establish multiple interactions with host cell receptors (36). The velocity of parasite opsonization and the massive C3 deposition suggest that promastigote-bound C3 has a pivotal role in the parasite–host interaction. *Leishmania* C3 binding is a prerequisite for promastigote IA (2, 3), receptor-mediated parasite binding to macrophages and endocytosis (37–39), and intracellular *Leishmania* survival (40). To correlate C3 deposition levels with parasite infectivity, we analyzed promastigote-C3 binding during the *L. amazonensis* life cycle, and found that promastigotes maintain a stable, CP-mediated C3 binding capacity throughout in vitro metacyclogenesis. Similar data, although measuring AP-mediated C3 deposition, have been reported for *L. donovani*, *L. major*, and *L. amazonensis* (9–11), although others found higher C3 binding to stationary promastigotes (37). *Leishmania* promastigotes in axenic cultures are believed to recapitulate the developmental sequence in the insect vector (41); promastigotes in the vector gut may thus behave as do the axenic promastigotes, and maintain invariant C3 binding capacity. Assuming that promastigote-bound C3 is responsible for receptor-mediated parasite binding to host cells and endocytosis, it is plausible that all C3-opsonized promastigotes egested from the sandfly gut into the blood pool have a similar probability of invading host leukocytes. In this case, the presence of infective metacyclic promastigotes would not be a necessary condition for infectivity.

Despite the abundant literature on promastigote killing by complement, time course studies of CP-mediated promastigote lysis at near-physiological conditions are lacking. Here we show real-time kinetic analyses of this mechanism (Fig. 3). Three aspects to be emphasized are the extreme velocity of the promastigote lytic reaction, the striking sensitivity of log phase *Leishmania* spp. populations to complement, and the differential complement susceptibility among stationary phase *Leishmania* spp. promastigote species. In all four species tested, PI uptake by stationary phase promastigotes begins within 30–60 s of serum contact and is complete by 2.5 min (Fig. 3 B, bottom panel), confirming previous results (2). *L. major* promastigotes incorporate PI more rapidly (Fig. 3 A, e), although this does not correlate with greater complement sensitivity. Using flagellar motility as a viability criterion, 15% (*L. major*) and 10% (*L. amazonensis*) of the promastigotes were viable after 2.5 min in 50% NHS. The data thus indicate that these species show a degree of complement resistance, and support the idea (24) that axenic *Leishmania* cultures give rise to developmental parasite forms that are resistant to human complement within the physiological infection period.

In contrast, *L. donovani* and *L. infantum* are highly sensitive to complement, which is also the case for promastigotes of all species tested in exponential growth (Fig. 3 B, top panel). From these data, we estimate that from 85% (stationary phase) to 100% (log phase) *Leishmania* spp. promastigotes are killed by complement after 2.5 min in human blood. To survive, *Leishmania* promastigotes must invade host cells within this period. Assuming a sandfly blood meal of 0.3 μ l, and sandfly thoracic midgut promastigote body volume of 4 μ m³ (42), each sandfly bite would inoculate at most 75 parasites. Estimating that at least 90% will be killed within 2.5 min, and that human blood phagocytes engulf promastigotes at a granulocyte:monocyte ratio of 2:1, in each bite, <4% of promastigotes inoculated (5 promastigotes) would enter a safe monocyte haven. It is thus clear that, during early stages of leishmaniosis transmission, serum opsonins exert very strong selective pressure on *Leishmania*, a mechanism that has presumably contributed to shaping the parasite's host evasion strategies.

Leishmania has been called a "parasite of paradox" for its ability to dwell in macrophages, the cell committed to its destruction (43); we would further justify this appellation. Complement protects vertebrates against protozoan invasion of the blood through the dual mechanisms of IA opsonic activity and the lytic cascade. Members of the *Muridae* family, such as the mouse and the hamster, have very low complement lytic activity against *Leishmania*, and may rely on IA opsonic activity to fend off infection (our unpublished data). In these genera, IA opsonic activity enhances promastigote phagocytosis and macrophage infection, which may explain the reservoir role of these rodents for *Leishmania*. In contrast, humans have a strong complement system and a potent IA mechanism; after inoculation, promastigote survival is linked to IA and endocytosis. We suggest that appropriation of IA-mediated opsonophagocytosis is the principal *Leishmania* strategy to evade

the innate host response. Its capacity to transform the vertebrate innate protective response into the key to host invasion provides an additional motive for the sobriquet "parasite of paradox."

The authors thank M. Díez for excellent technical assistance; N. Sánchez and M.A. Ortega for blood extraction, Drs. R. Molina (Serv. Parasitología, Centro Nacional de Microbiología) for sandfly bloodmeal data, A. Orfao (Serv. General de Citometría, Universidad de Salamanca, Spain) and J.M. Ligos (BD, Spain) for advice on real-time cytofluorometric analysis; and C. Mark for editorial assistance, critical reading and sound advice on the manuscript.

This work was supported by grants 08.2/0006/97 from the Comunidad Autónoma de Madrid, PM99-0012 from the Programa Nacional de Salud (Ministerio de Educación y Cultura), and institutional funds from the Centro Nacional de Microbiología, Instituto de Salud Carlos III.

Submitted: 31 July 2001

Revised: 11 December 2001

Accepted: 4 January 2002

References

1. Mosser, D.M., and A. Brittingham. 1997. *Leishmania*, macrophages and complement: a tale of subversion and exploitation. *Parasitology*. 115:S9–S23.
2. Domínguez, M., and A. Torano. 1999. Immune adherence-mediated opsonophagocytosis: the mechanism of *Leishmania* infection. *J. Exp. Med.* 189:25–35.
3. Domínguez, M., and A. Torano. 2001. *Leishmania* immune adherence reaction in vertebrates. *Parasite Immunol.* 23:259–265.
4. Handman, E. 2000. Cell biology of *Leishmania*. *Adv. Parasitol.* 44:2–39.
5. Pearson, R.D., and R.T. Steigbigel. 1980. Mechanism of lethal effect of human serum upon *Leishmania donovani*. *J. Immunol.* 125:2195–2201.
6. Navin, T.R., E.C. Krug, and R.D. Pearson. 1989. Effect of immunoglobulin M from normal human serum on *Leishmania donovani* promastigote agglutination, complement-mediated killing, and phagocytosis by human monocytes. *Infect. Immun.* 57:1343–1346.
7. Mosser, D.M., and P.J. Edelson. 1984. Activation of the alternative complement pathway by *Leishmania* promastigotes: parasite lysis and attachment to macrophages. *J. Immunol.* 132:1501–1505.
8. Mosser, D.M., S.K. Burke, E.E. Coutavas, J.F. Wedgwood, and P.J. Edelson. 1986. *Leishmania* species: mechanisms of complement activation by five strains of promastigotes. *Exp. Parasitol.* 62:394–404.
9. Puentes, S.M., D.M. Dwyer, P.A. Bates, and K.A. Joiner. 1989. Binding and release of C3 from *Leishmania donovani* promastigotes during incubation in normal human serum. *J. Immunol.* 143:3743–3749.
10. Puentes, S.M., D.L. Sacks, R.P. da Silva, and K.A. Joiner. 1988. Complement binding by two developmental stages of *Leishmania major* promastigotes varying in expression of a surface lipophosphoglycan. *J. Exp. Med.* 167:887–902.
11. Nunes, A.C., and F.J. Ramalho-Pinto. 1996. Complement resistance of *Leishmania amazonensis* promastigotes is independent of parasite proteases and lysis of sensitive forms in not due to natural antibodies in normal human serum. *Braz. J.*

12. Noronha, F.S.M., A.C. Nunes, K.T. Souza, M.N. Melo, and F.J. Ramalho-Pinto. 1998. Differential sensitivity of New World *Leishmania* spp promastigotes to complement-mediated lysis: correlation with the expression of three parasite polypeptides. *Acta Trop.* 69:17–29.
13. Green, P.J., T. Feizi, M.S. Stoll, S. Thiel, A. Prescott, and M.J. McConville. 1994. Recognition of the major cell surface glycoconjugates of *Leishmania* parasites by the human serum mannan-binding protein. *Mol. Biochem. Parasitol.* 66: 319–328.
14. Culley, F.J., R.A. Harris, P.M. Kaye, P.W.J. McAdam, and J.G. Raynes. 1996. C-reactive protein binds to a novel ligand on *Leishmania donovani* and increases uptake into human macrophages. *J. Immunol.* 156:4691–4696.
15. Bee, A., F.J. Culley, I.S. Alkahalife, K.B. Bodman-Smith, J.G. Raynes, and P.A. Bates. 2001. Transformation of *Leishmania mexicana* metacyclic promastigotes to amastigote-like forms mediated by binding of human C-reactive protein. *Parasitology.* 122:521–529.
16. Leyva-Cobián, F., I. Moneo, F. Mampaso, M. Sánchez-Bayle, J.L. Eciija, and A. Bootello. 1981. Familial C1q deficiency associated with renal and cutaneous disease. *Clin. Exp. Immunol.* 44:173–180.
17. Sobel, A.T., M. Moisy, G. Hirbec, A. Tournesac, J.P. Berry, P. Mannoni, A.P. Peltier, and G. Lagrue. 1979. Hereditary C2 deficiency associated with non-systemic glomerulonephritis. *Clin. Nephrol.* 12:132–136.
18. Hudson, L., and F.C. Hay. 1989. Practical Immunology. 3rd ed. Blackwell, Oxford. 319–321.
19. Smith, P.K., R.I. Krohn, G.T. Hermanson, A.K. Mallia, F.H. Gartner, M.D. Provenzano, E.K. Fujimoto, N.M. Goetze, B.J. Olson, and D.C. Klenk. 1985. Measurement of protein using bicinchoninic acid. *Anal. Biochem.* 150:76–85.
20. Partridge, C.S., D.W. Britton, and K.D. Bagshawe. 1985. Use of the direct linear plot to estimate, in an immunoglobulin solution, the proportion which is specific monoclonal antibody against an unknown cell surface antigen. *J. Immunol. Methods.* 78:95–101.
21. Eisenthal, R., and A. Cornish-Bowden. 1974. The direct linear plot. A new graphical procedure for estimating enzyme kinetic parameters. *Biochem. J.* 139:715–720.
22. Ways, J.P., and P. Parham. 1983. The binding of monoclonal antibodies to cell-surface molecules. A quantitative analysis with immunoglobulin G against two alloantigenic determinants of the human transplantation antigen HLA-A2. *Biochem. J.* 216:423–432.
23. Fine, D.P., S.R. Marney, Jr., D.G. Colley, J.S. Sargent, and R.M. Des Prez. 1972. C3 shunt activation in human serum chelated with EGTA. *J. Immunol.* 109:807–809.
24. Franke, E.D., P.B. McGreevy, S.P. Katz, and D.L. Sacks. 1985. Growth cycle-dependent generation of complement-resistant *Leishmania* promastigotes. *J. Immunol.* 134:2713–2718.
25. Bandyopadhyay, P., D.K. Ghosh, A. De, K.N. Ghosh, P.P. Chaudhuri, P. Das, and A. Bhattacharya. 1991. Metacyclogenesis of *Leishmania* spp: species-specific *in vitro* transformation, complement resistance, and cell surface carbohydrate and protein profiles. *J. Parasitol.* 77:411–416.
26. Howard, M.K., G. Sayers, and M.A. Miles. 1987. *Leishmania donovani* metacyclic promastigotes: transformation *in vitro*, lectin agglutination, complement resistance, and infectivity. *Exp. Parasitol.* 64:147–156.
27. Bates, P.A., and L. Tetley. 1993. *Leishmania mexicana*: induction of metacyclogenesis by cultivation of promastigotes at acidic pH. *Exp. Parasitol.* 76:412–423.
28. Barral-Netto, M., S.B. Roters, I. Sherlock, and S.G. Reed. 1987. Destruction of *Leishmania mexicana amazonensis* promastigotes by normal human serum. *Am. J. Trop. Med. Hyg.* 37:53–56.
29. Shaw, J. 1994. The meeting of two worlds: eco-epidemiology and molecules. *Mem. Inst. Oswaldo Cruz.* 89:7–9 (Abstr.).
30. Drickamer, K. 1999. C-type lectin-like domains. *Curr. Opin. Struct. Biol.* 9:585–590.
31. Lu, J., S. Thiel, H. Wiedemann, R. Timpl, and K.B.M. Reid. 1990. Binding of the pentamer/hexamer forms of mannan-binding protein to zymosan activates the proenzyme C1r₂C1s₂ complex, of the classical pathway of complement, without involvement of C1q. *J. Immunol.* 144:2287–2294.
32. Thiel, S., U. Holmskov, L. Hviid, S.B. Laursen, and J.C. Jensenius. 1992. The concentration of the C-type lectin, mannan-binding protein, in human plasma increases during an acute phase response. *Clin. Exp. Immunol.* 90:31–35.
33. Pepys, M.B. 1981. C-reactive protein fifty years on. *Lancet.* 1:653–656.
34. Peters, C., M. Kawakami, M. Kaul, T. Ilg, P. Overath, and T. Aebischer. 1997. Secreted proteophosphoglycan of *Leishmania mexicana* amastigotes activates complement by triggering the mannan binding lectin pathway. *Eur. J. Immunol.* 27: 2666–2672.
35. De Miranda Santos, I.K.F., C.H.N. Costa, H. Krieger, M.Y. Feitosa, D. Zurakowski, B. Fardin, R.B.B. Gomes, D.L. Weiner, D.A. Harn, R.A.B. Ezekowitz, and J. Epstein. 2001. Mannan-binding lectin enhances susceptibility to visceral leishmaniasis. *Infect. Immun.* 69:5212–5215.
36. Handman, E. 2001. *Leishmania* virulence: it's a knock out! *Trends Parasitol.* 17:60.
37. Wozencraft, A.O., and J.M. Blackwell. 1987. Increased infectivity of stationary-phase promastigotes of *Leishmania donovani*: correlation with enhanced C3 binding capacity and CR3-mediated attachment to host macrophages. *Immunology.* 60:559–563.
38. Mosser, D.M., T.A. Springer, and M.S. Diamond. 1992. *Leishmania* promastigotes require opsonic complement to bind to the human leukocyte integrin Mac-1 (CD11b/CD18). *J. Cell Biol.* 116:511–520.
39. Rosenthal, L.A., F.S. Sutterwala, M. Kehrl, and D.M. Mosser. 1996. *Leishmania major*-human macrophage interactions: cooperation between Mac-1 (CD11b/CD18) and complement receptor type 1 (CD35) in promastigote adhesion. *Infect. Immun.* 64:2206–2215.
40. Mosser, D.M., and P.J. Edelson. 1987. The third component of complement (C3) is responsible for the intracellular survival of *Leishmania major*. *Nature.* 327:329–331.
41. Sacks, D.L. 1989. Metacyclogenesis in *Leishmania* promastigotes. *Exp. Parasitol.* 69:100–103.
42. Warburg, A., and Y. Schlein. 1986. The effect of post-blood-meal nutrition of *Phlebotomus papatasi* on the transmission of *Leishmania major*. *Am. J. Trop. Med. Hyg.* 35:926–930.
43. Chang, K.-P. 1990. Cell biology of *Leishmania*. In *Modern Parasite Biology*. D.J. Wyler, editor. W. H. Freeman & Co, New York. 79–90.